1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,000 | 8,000 | 09:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 242 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 03.07. | Dividendenbekanntmachungen (03.07.2026) | 8.381 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABL DIAGNOSTICS SA FR001400AHX6 - 0,11 EUR AGORA SA PLAGORA00067 0,5 PLN 0,1165 EUR ALBIS LEASING AG DE0006569403 - 0,1 EUR BILIA... ► Artikel lesen | |
| 02.07. | ABL Diagnostics - Approval of Dividend Distribution for Fiscal Year 2025 | 522 | Business Wire | Regulatory News:
At the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including... ► Artikel lesen | |
| 18.06. | ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified | 381 | Business Wire | Target price: €8.7 Recommendation: Buy
Regulatory News:
ABL DIAGNOSTICS (FR001400AHX6 ABLD-FR), a leading company in the field of molecular diagnostics and genotyping, announces the... ► Artikel lesen | |
| ABL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 12.06. | ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031 | 405 | Business Wire | Regulatory News:
ABL Diagnostics (FR001400AHX6 "ABLD") announces the signing of a multi-year contract with a European pharmaceutical company in the field of neurodegenerative diseases. The contract... ► Artikel lesen | |
| 10.06. | ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France | 445 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) (Euronext Paris Compartment B ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions, healthcare software, and clinical sample... ► Artikel lesen | |
| 10.06. | ABL Diagnostics SA: ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Total Number of Shares Composing the Share Capital | 475 | Business Wire | (Articles L. 233-8, II of the French Commercial Code and 223-16 of the AMF General Regulation)
Regulatory News:
ABL Diagnostics (Paris:ABLD)
Date Total number of shares composing... ► Artikel lesen | |
| 09.06. | ABL Diagnostics: Ordinary and Extraordinary General Meeting of June 30, 2026 - Terms for Making Available or Consulting Preparatory Documents | 378 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) informs its shareholders that they are invited to attend the Ordinary and Extraordinary General Meeting to be held on Tuesday, June 30, 2026, at 11:00... ► Artikel lesen | |
| 05.06. | ABL Diagnostics SA: ABL Diagnostics: Sale of a new block of shares by its main shareholder ABL | 409 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 04.06. | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 354 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 01.06. | ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026 | 341 | Business Wire | Full-year 2026 revenue target set at €12.27 million, delivering an exceptional +76.5% growth compared to 2025 Historic shift in scale driven by the full-year impact of growth drivers (FTD... ► Artikel lesen | |
| 19.05. | Allinvest Reiterates Its "BUY" Rating on ABL Diagnostics and Maintains a €8.4 Target Price (Representing a 2.2X Multiple) | 346 | Business Wire | Massive upside potential of +123.4% compared to the closing price of €3.76 (as of May 18, 2026). Historic 2025 results: Revenue up +30.4% to €6.95m, net profit surging to €0.98m (+246%)... ► Artikel lesen | |
| 18.05. | ABL Diagnostics SA: ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025 | 317 | Business Wire | Proposed dividend of €0.11 per share, up +120%, reflecting the Company's improved financial performance and solid financial position
Regulatory News:
ABL Diagnostics (Euronext Paris FR001400AHX6)... ► Artikel lesen | |
| 11.05. | ABL Diagnostics Reports Historic 2025 Annual Results: Net Income Explosion (+246%), Strong Operating Profitability and Global Acceleration | 348 | Business Wire | Strong revenue growth of +30.4% to €6.95m Positive operating income of €290k, exceeding analyst forecasts Net income soaring to nearly €1m (€987k) International business acceleration:... ► Artikel lesen | |
| 08.05. | ABL Diagnostics: Availability of the 2025 Annual Financial Report | 432 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF).
The... ► Artikel lesen | |
| 17.03. | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 402 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 19.02. | ABL Diagnostics S.A.: ABL Diagnostics Update Regarding Non-Binding Letter of Intent | 389 | Business Wire | Regulatory News:
ABL Diagnostics S.A. (Euronext: ABLD ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological... ► Artikel lesen | |
| 13.02. | ABL Diagnostics SA: ABL SA Executes the First Purchase Notice of ABL Diagnostics Shares With Alumni Capital | 630 | Business Wire | Regulatory News:
ISIN: FR001400AHX6 Euronext Paris
ABL Diagnostics SA ("the Company") (Paris:ABLD) informs the public that its principal shareholder, Advanced Biological Laboratories SA (ABL... ► Artikel lesen | |
| 03.02. | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 450 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 19.12.25 | ABL Diagnostics Informs the Market of a Non-Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger | 513 | Business Wire | The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.'s control over ABL Diagnostics at... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 35,260 | -0,84 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Siemens Healthineers von 51 auf 38 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Mehrere Risikofaktoren belasteten... ► Artikel lesen | |
| THERMO FISHER | 464,50 | +0,02 % | Persistence Market Research Pvt. Ltd.: Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG | LONDON, July 8, 2026 /PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient... ► Artikel lesen | |
| STRATEC | 19,200 | 0,00 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| UNIDOC HEALTH | 0,068 | +17,71 % | Unidoc Health Corp: Unidoc CFO Thornberry resigns | ||
| DIASORIN | 69,04 | -0,17 % | DiaSorin speculated to have rebuffed takeover offer from US suitor - report | ||
| BIOCARTIS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.01.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 21.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.01.2026ISIN NameBE0974281132 BIOCARTIS... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 69,63 | -0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| HEARTFLOW | 26,160 | 0,00 % | Heartflow, Inc.: New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management | ||
| BILLIONTOONE | 123,25 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,380 | 0,00 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| PROGYNY | 31,990 | +0,03 % | KeyBanc raises Progyny stock price target on utilization strength | ||
| ONCOLOGY INSTITUTE | 6,250 | 0,00 % | BTIG hebt Kursziel für Oncology Institute Aktie nach Umschuldung auf 9 US-Dollar an | ||
| BETA BIONICS | 16,960 | +0,06 % | Beta Bionics, Inc.: Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 27,890 | 0,00 % | Privia Health Group, Inc. - 8-K, Current Report | ||
| GENEDX | 63,81 | -0,06 % | Piper Sandler raises GeneDx stock price target on coverage policy |
Das Unternehmen ABL DIAGNOSTICS SA kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,760 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,22 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von +7,97 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABL DIAGNOSTICS SA finden Sie auf Wallstreet Online.